Stocks priced under $30 often get overlooked, but Pfizer and Nu Holdings stand out with solid balance sheets and growth potential. Pfizer, a global biopharma giant, trades around $25 with a strong dividend yield and promising pipeline despite some revenue risks. Nu Holdings, parent of Nubank, offers rapid growth in Latin America with improving profitability and a new U.S. banking charter, despite some credit and currency risks. Both present attractive opportunities for investors seeking stability and growth in a challenging economic environment.
In May 2026, despite overall high market valuations, five stocks trading under $30 stand out for their strong financial health and growth prospects. Pfizer offers a 6.68% dividend yield and growth from its non-COVID portfolio and obesity pipeline, wh...
Pfizer continues to be favored by investors due to its strong performance in the oncology drug market, highlighted by a 16.3% quarterly and 38.7% yearly sales increase of Padcev, driven by demand in combination with Merck's Keytruda. Despite recent F...
Michael Burry has invested in Pfizer, Molina Healthcare, and Halliburton for their strong cash flow, pricing power, and stable margins amid ongoing inflation. Pfizer offers a 6.66% dividend yield and growth potential as COVID impacts fade, trading at...
